Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval

The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。